본문 바로가기
  • Home

A Case Report on the Improvement of Dyshidrotic Eczema Using Ortho-Cellular Nutrition Therapy (OCNT)

  • CELLMED
  • Abbr : CellMed
  • 2025, 15(11), pp.5~5
  • DOI : 10.5667/CellMed.spc.139
  • Publisher : Cellmed Orthocellular Medicine and Pharmaceutical Association
  • Research Area : Medicine and Pharmacy > General Medicine
  • Received : August 27, 2025
  • Accepted : August 29, 2025
  • Published : August 29, 2025

Yeonhee Seo 1

1명성온누리약국

Irregular Papers

ABSTRACT

Objective: Dyshidrotic eczema is a skin disorder characterized by small vesicles, pruritus, and erythema on the hands or feet. Although its exact cause has not been fully determined, factors such as contact allergy and underlying skin conditions are considered contributing elements. Treatment options include basic skin moisturization, administration of antihistamines, topical corticosteroids, and phototherapy. Because treatment efficacy and side effects vary among patients, it is essential to select the most appropriate therapy tailored to each individual. Case Report: The patient in this case study was a woman in her thirties with a 10-year history of dyshidrotic eczema. She presented with erythema and vesicles on her hands, accompanied by severe pruritus. Despite ongoing hospital visits and pharmacological treatment, her symptoms progressively worsened. Consequently, Ortho-Cellular Nutrition Therapy (OCNT) was applied, incorporating fennel, clove, anthocyanins, omega-3, glycyrrhizin, curcumin, MSM, hyaluronic acid, and selenium. Following this regimen, the patient’s dyshidrotic eczema symptoms improved markedly, and she has since maintained a stable condition without major recurrence. Conclusion: Although this case study involved only a single patient and therefore has limitations in generalizing OCNT to all dyshidrotic eczema cases, an individualized OCNT regimen, tailored to the patient’s symptoms and overall health status, may offer benefits in the management of dyshidrotic eczema.

Citation status

* References for papers published after 2024 are currently being built.